- Bad debt is written off worth 17crs
- India business: Leading company in Macrolides (a segment of anti-infectives) as well as other acute therapies.
- Made a mark in some specialized therapies such as Diabetology, Cardiology, and Gynaecology as well. (chronic & sub-chronic therapies)
- A high specialty Ophthalmic range has been introduced in the Ophthalcare Division in the domestic market. (See if they are able to scale up)
- US Business: Received 15 ANDAs approval.
- Strategy in International Generics is to partner with International Generic companies and leverage their marketing and sales capabilities.
- It shares the investment and returns with the marketing partners and this helps de-risk its ANDA program and reduces the upfront investment in the development stage. (Capital light approach)
- Timely and accelerated quality filling ANDAs / DMF will be a key focus area.
- The company has 300 scientists working across two development centers.